Navigation Links
Journal of Cardiovascular Electrophysiology Study Shows Promising Single Ablation Procedure Outcomes With HeartLight EAS for Treatment of Atrial Fibrillation
Date:1/17/2012

MARLBOROUGH, Mass., Jan. 17, 2012 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight™ Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces that a new study in the Journal of Cardiovascular Electrophysiology demonstrates the high acute and chronic success rates achievable with a single AF ablation procedure using HeartLight EAS. The study was conducted by Boris Schmidt, MD, and colleagues at Cardioangiologisches Centrum Bethanien, Frankfurt, Germany, and was published online in January 2012.

The HeartLight EAS is a catheter ablation system that incorporates, for the first time, an endoscope for direct visualization of a beating heart, in real-time and without radiation. It also includes a compliant, dynamically adjustable balloon catheter designed for improved contact with the pulmonary vein (PV) ostium (opening) irrespective of the individual patient anatomy, and utilizes laser energy for more efficient, durable and precise ablation treatment.

"Pulmonary vein isolation is a critical indicator of success in catheter ablation procedures for AF; however, this has traditionally been a very challenging and complex endeavor requiring an experienced operator, multiple ablation devices to account for varied patient anatomy, and even multiple transseptal punctures for access," said Dr. Schmidt. "In this study we set out to examine the feasibility of performing a streamlined, visually-guided ablation procedure and record best practices to achieve endpoints of acute and chronic success.  Our findings demonstrate that this unique approach to ablation may prove highly effective in treating AF patients."

In the study, "Visually Guided Sequential Pulmonary Vein Isolation: Insights into Techniques and Predictors of Acute Success," physicians performed ablation with a single HeartLight EAS and single transseptal puncture on 35 patients with drug-refractory paroxysmal or persistent AF. PV isolation was achieved in 70% (96/137) of veins with an initial ablation. After assessment with a circular mapping catheter, continued ablation with the same HeartLight EAS device resulted in an overall 98% single procedure PV isolation rate. 

Procedures were performed in a mean time of 154+ 38 min, with the ablation stage lasting an average of 89+ 16 min and mean fluoroscopy time of 16 + 6 min. Notably, between the first and last 12 cases a reduction in procedure time was observed (175 + 48 min vs. 138 + 26 min). The primary efficacy endpoint of the study was acute PVI, with a secondary endpoint of freedom from AF between 90 and 365 days post-ablation and off antiarrythmic drugs. During a median follow-up of 266 days, 77% (27/35) of patients remained free of any tachyarrhythmia recurrence and off drugs.

"With the increasing use of catheter ablation as a treatment option for AF patients, the short learning curve and simplified approach enabled by the HeartLight EAS makes this a very promising system, especially as the technique continues to be adopted outside specialized ablation centers," continued  Dr. Schmidt. "In the paper we documented our approach to performing ablation on our center's first series of patients to undergo treatment with the HeartLight EAS, and we believe that as the procedure continues to be standardized, additional centers will experience these impressive, reproducible results."

"In this study, physicians have demonstrated a high rate of clinical success achievable within a reasonably short procedure time, even among operators still in the midst of the learning curve," said Stephen Sagon, President and CEO of CardioFocus. "This reinforces the advantages of HeartLight EAS' novel, adaptable and user-friendly design, and we look forward to continued positive experiences from this and other medical centers as they begin to standardize and master this ablation approach."

For more information on HeartLight EAS, please visit www.CardioFocus.com.

About CardioFocus, Inc.CardioFocus, Inc. is a medical device manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF). Its novel HeartLight Endoscopic Ablation System for catheter ablation incorporates an endoscope to provide physicians with the capacity to see within the heart, and for the first time, visually direct the application of laser energy to achieve durable pulmonary vein isolation.

The HeartLight Endoscopic Ablation System is commercially available at leading institutions throughout Europe. The device is investigational in the U.S., with a pivotal study expected to commence in 2012. CardioFocus is headquartered in Marlborough, MA, USA.  For more information on the company and its technology, please visit www.CardioFocus.com.

The scientific information discussed in this news release is preliminary and investigative. The CardioFocus HeartLight Endoscopic Ablation System is not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the system. Only FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Healthcare professionals should refer to/rely upon FDA-approved labeling for the products, and not the information discussed in this news release.

B Schmidt et al: Visually Guided Sequential Pulmonary Vein Isolation: Insights into Techniques and Predictors of Acute Success. Journal of Cardiovascular Electrophysiology. 2012 Jan 9; DOI: 10.1111/j.1540-8167.2011.02247.x http://onlinelibrary.wiley.com/doi/10.1111/j.1540-8167.2011.02247.x/abstract

 Company Contact:

Media Contact:Anjie Roldan

 Lisa CookVice President Finance

(646) 536-7012(508) 658-7237

lcook@theruthgroup.com aroldan@cardiofocus.com

 


'/>"/>

SOURCE CardioFocus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoGenex Announces Publication of Phase I/II Custirsen (OGX-011/TV-1011) Data in Journal of Thoracic Oncology
2. The New England Journal of Medicine Publishes Study Showing LigoCytes Norovirus Vaccine Demonstrates Protection Against Illness
3. Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients
4. Dermatologist Amy Taub, MD, is Published in the Journal of Clinical and Aesthetic Dermatology
5. Butrans® (Buprenorphine) Transdermal System CIII Pivotal Phase 3 Data Published in the Journal of Pain and Symptom Management
6. American Skin Association Honors Leading Physicians and Scientists; Journalist Deborah Norville
7. Data Published in Circulation Journal Show OrbusNeichs Genous™ Stent Is Safe and Effective in Elderly Patients
8. Ion Torrent CEO Jonathan Rothberg, Life Technologies Recognized by Wall Street Journal Technology Innovation Awards for the Ion Personal Genome Machine
9. Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology
10. Journal of Clinical Oncology Publishes Phase 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Capecitabine in Patients with Metastatic Colorectal Cancer
11. Atrium Announces the Publication of the COBEST Trial by the Journal of Vascular Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Consumers have taken a ... have placed more emphasis on patient outcomes. ... programs in the pharmaceutical industry have evolved beyond ... pharmaceutical companies are focusing on becoming more patient-oriented ... products and services that improve health. ...
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American Respiratory ... testing company, is now able to perform sophisticated lung assessments in ... Medical Technologies , Inc. Patients are no longer ... to ndd,s EasyOne PRO ® , ARL patients like Jeanne R. ... testing done in the comfort of her own home. ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... "FCPX editors can ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Final Cut Pro X users can now reveal the media of their ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
Breaking Medicine News(10 mins):